H1120000

Hydralazine hydrochloride

European Pharmacopoeia (EP) Reference Standard

Synonym(s):
1-Hydrazinophthalazine hydrochloride
Empirical Formula (Hill Notation):
C8H8N4 · HCl
CAS Number:
Molecular Weight:
196.64
MDL number:
PubChem Substance ID:
NACRES:
NA.24
Pricing and availability is not currently available.

grade

pharmaceutical primary standard

form

neat

CofA

certificate is enclosed in each package

mfr. no.

EDQM

Featured Industry

Pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

ClH.N\N=C1/N=NC=C2C=CC=CC12

InChI

1S/C8H8N4.ClH/c9-11-8-7-4-2-1-3-6(7)5-10-12-8;/h1-5,7H,9H2;1H/b11-8-;

InChI key

SECXUXOCDLQOBI-MKFZHGHUSA-N

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.
For further information and support please go to the website of the
issuing Pharmacopoeia.

Biochem/physiol Actions

Inhibits DNA methyltransferase and modulates epigenetic regulation of gene expression. Non-selective MAO-A/B inhibitor; antihypertensive; semicarbazide-sensitive amine oxidase inhibitor.

Packaging

Unit quantity: 20 mg. Subject to change. The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference subtance catalogue.

Caution

Other Notes

Sales restrictions may apply.

Pictograms

Skull and crossbones

Signal Word

Danger

Hazard Statements

Target Organs

Respiratory system

RIDADR

UN 2811 6.1 / PGIII

WGK Germany

WGK 3

Certificate of Analysis
Certificate of Origin
Hydralazine and hydralazine hydrochloride.
IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans, 24, 85-100 (1980-01-01)
Fumiki Yoshihara et al.
Clinical and experimental nephrology, 19(2), 197-207 (2014-05-23)
The infusion of chronic angiotensin II (Ang II) has been shown to promote renal interstitial fibrosis. To evaluate the pathophysiological significance of the natriuretic peptide-GC-A system, we infused Ang II (1.0 mg/kg/day) in GC-A-deficient mice (GC-A-KO). We used 5 groups...
Genetic mechanisms possibly leading to racially different responses to nitrate therapy.
Gustavo H Oliveira-Paula
The American journal of cardiology, 114(7), 1126-1126 (2014-09-13)
Keith C Ferdinand
Expert review of cardiovascular therapy, 3(6), 993-1001 (2005-11-19)
In the USA alone, there are over 5,000,000 people diagnosed with heart failure. A disproportionate number of African-Americans are affected by this disease, with increased morbidity and mortality, yet they are tremendously under-represented in clinical trials. Several drugs have been...
Sofie Gevaert et al.
Acta cardiologica, 69(2), 193-196 (2014-05-03)
Heart failure is an established predictor of primary cardiac events during pregnancy. Adequate heart failure treatment in pregnant women is hampered by important foetotoxicity of several conventional drugs. Hydralazine with or without long-acting nitrates has been proposed as an alternative...

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

MilliporeSigma

Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.